Valneva SE (VALN) News
Track canonical SquawkNews coverage tagged to VALN, Valneva SE. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 4 indexed stories across 2 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
University of Michigan sentiment falls to 51 in early August
The University of Michigan's consumer sentiment index declined to 51 in early August from 55.2 in the previous month, missing market estimates of 54.5.
EARNINGS | Aug 14, 2026, 04:02 PM UTC
M
Pfizer (PFE) and Valneva (VALN) EMA validates Lyme vaccine MAA
EMA validates the marketing authorization application for PF-07307405, based on the Phase 3 VALOR trial in more than 9,400 participants aged five years and older, reporting more than 70% efficacy and no safety concerns.
REGULATION | Aug 14, 2026, 09:17 AM UTC
L
Valneva affirms FY2026 sales guidance at $169.795M-$187.360M
Valneva affirms its FY2026 sales outlook at $169.795 million-$187.360 million versus a $171.630 million estimate.
EARNINGS | Aug 13, 2026, 02:20 PM UTC
L
Valneva reports H1 2026 product sales €64.0M, net loss €63.3M
Valneva reports H1 2026 total product sales of €64.0 million, down from €91.0 million YoY, and a net loss widening to €63.3 million from €20.8 million YoY, while reaffirming full-year guidance of €135–150 million.
EARNINGS | Aug 13, 2026, 05:11 AM UTC